IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2024-03-06 (biospace.com)
Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024 | BioSpace
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
Read more
2024-02-14 (natlawreview.com)
Antitrust M&A Snapshot | Q4 2023
UNITED STATES New Merger Guidelines Released
Read more
2023-12-11 (globalcompetitionreview.com)
FTC and IQVIA close out trial
The Federal Trade Commission says it has demonstrated that a preliminary injunction is the “absolute minimum” required to thwart the anticompetitive issues at stake in the proposed IQVIA/Propel Media merger.
Read more
2023-12-07 (nakedcapitalism.com)
2:00PM Water Cooler 12/7/2023 | naked capitalism
Fearless commentary on finance, economics, politics and power
Read more
2023-10-30 (globalcompetitionreview.com)
FTC promises trove of docs to block IQVIA merger
The Federal Trade Commission says that “document after document” will demonstrate at trial next month how closely IQVIA competes with Propel Media for advertising targeting healthcare professionals.
Read more
2017-03-13 (outsourcing-pharma.com)
All news
All News 20-Sep-2022 By Nick Taylor Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper. 20-Sep-2022 By Nick Taylor Science
Read more